A court has ordered several US government agencies, including the US Food and Drug Administration (FDA), to restore healthcare resources relating to diversity, including its application in ...

FDA rejects AXS-14 NDA citing issues with one of the two key clinical trials. Axsome to initiate new trial in late 2025; fibromyalgia drug launch now seen in 2028.